Advanced or Metastatic KRAS-mutant Tumor Clinical Trials in Headington, Oxford

Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.